Publications by authors named "Anna Couvillon"
Background: Before 2018, there was no standard of care for non-metastatic (M0) castration resistant prostate cancer nmCRPC. Androgen receptor antagonists (ARAs) were commonly used sequentially nmCRPC.
Methods: This was a multicenter, randomized clinical trial comparing the ARA flutamide+/-PROSTVAC, a pox viral vaccine targeting PSA that includes T-cell co-stimulatory molecules.
Article Synopsis
- The study examined the effectiveness of enzalutamide combined with immunotherapy in treating non-metastatic castration-sensitive prostate cancer (nmCSPC) without using androgen deprivation therapy (ADT).
- Patients with rising PSA levels were randomized to receive either enzalutamide alone or alongside PROSTVAC, showing significant PSA declines of 99% across both groups.
- Enzalutamide treatment led to immune system changes, including increased natural killer and naïve T cells, and was generally well-tolerated, with the most common side effects being mild fatigue and breast tenderness.
Purpose: For high-risk prostate cancer, standard treatment options include radical prostatectomy (RP) or radiotherapy plus androgen deprivation therapy (ADT). Despite definitive therapy, many patients will have disease recurrence. Imaging has the potential to better define characteristics of response and resistance.
View Article and Find Full Text PDFObjective: To evaluate the safety and efficacy of cabozantinib combined with docetaxel.
Patients And Methods: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg).
Prostate cancer is the most common malignancy and the second leading cause of cancer related deaths in the United States. Established risk factors for prostate cancer incidence include older age, African-American race, and positive family history. Prostate cancer has substantial inherited predisposition and certain genetic variants are associated with increased risk of disease.
View Article and Find Full Text PDFPurpose: Prostate-Specific Membrane Antigen (PSMA) PET/CT has been introduced as a sensitive method for characterizing metastatic prostate cancer. The purpose of this study is to compare the spatial concordance of F-NaF PET/CT and F-PSMA-targeted PET/CT within prostate cancer bone metastases.
Methods: Prostate cancer patients with known bone metastases underwent PSMA-targeted PET/CT (F-DCFBC or F-DCFPyL) and F-NaF PET/CT.
Background: Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S.
View Article and Find Full Text PDFThe purpose of this study was to compare the diagnostic performance of F-DCFBC PET/CT, a first-generation F-labeled prostate-specific membrane antigen (PSMA)-targeted agent, and F-NaF PET/CT, a sensitive marker of osteoblastic activity, in a prospective cohort of patients with metastatic prostate cancer. Twenty-eight prostate cancer patients with metastatic disease on conventional imaging prospectively received up to 4 PET/CT scans. All patients completed baseline F-DCFBC PET/CT and F-NaF PET/CT scans, and 23 patients completed follow-up imaging, with a median follow-up interval of 5.
View Article and Find Full Text PDFObjective: To determine the safety and clinical efficacy of two anti-angiogenic agents, bevacizumab and lenalidomide, with docetaxel and prednisone.
Patients And Methods: Eligible patients with metastatic castration-resistant prostate cancer enrolled in this open-label, phase II study of lenalidomide with bevacizumab (15 mg/kg), docetaxel (75 mg/m(2) ) and prednisone (10 mg daily). Docetaxel and bevacizumab were administered on day 1 of a 3-week treatment cycle.
Purpose Of Review: This article reviews recent developments in the use of active surveillance for localized prostate cancer.
Recent Findings: The treatment of localized prostate cancer continues to be a major challenge for urologic oncologists. Screening with prostate-specific antigen has resulted in increased numbers of low-risk prostate cancers being detected.